Do analysts prefer CASI or BFRI?

CASI Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer CASI or BFRI?

In the previous week, Biofrontera had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for CASI Pharmaceuticals. Biofrontera's average media sentiment score of 0.91 beat CASI Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CURX or CASI?

CASI Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CASI or IMNN?

In the previous week, Imunon had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Imunon and 1 mentions for CASI Pharmaceuticals. Imunon's average media sentiment score of 0.62 beat CASI Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CASI or CELZ?

CASI Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate PMCB or CASI?

CASI Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor PMCB or CASI?

In the previous week, Nuvilex and Nuvilex both had 1 articles in the media. Nuvilex's average media sentiment score of 0.87 beat CASI Pharmaceuticals' score of 0.00 indicating that Nuvilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvilex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 06/3/2026

Compare

CASI vs. BFRI, CURX, IMNN, CELZ, and PMCB

Should you buy CASI Pharmaceuticals stock or one of its competitors? MarketBeat compares CASI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CASI Pharmaceuticals include Biofrontera (BFRI), Curanex Pharmaceuticals (CURX), Imunon (IMNN), Creative Medical Technology (CELZ), and Nuvilex (PMCB). These companies are all part of the "pharmaceutical products" industry.

How does CASI Pharmaceuticals compare to Biofrontera?

CASI Pharmaceuticals (NASDAQ:CASI) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Biofrontera has a net margin of -25.66% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Biofrontera	-25.66%	-515.34%	-53.91%

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biofrontera had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for CASI Pharmaceuticals. Biofrontera's average media sentiment score of 0.91 beat CASI Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

CASI Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than CASI Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A

Summary

Biofrontera beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Curanex Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

CASI Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Curanex Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.89 beat CASI Pharmaceuticals' score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Very Positive
CASI Pharmaceuticals	Neutral

Curanex Pharmaceuticals has higher earnings, but lower revenue than CASI Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Summary

CASI Pharmaceuticals beats Curanex Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Imunon?

CASI Pharmaceuticals (NASDAQ:CASI) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Imunon had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Imunon and 1 mentions for CASI Pharmaceuticals. Imunon's average media sentiment score of 0.62 beat CASI Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Imunon has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Imunon	N/A	-341.23%	-153.79%

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Imunon has a consensus price target of $10.00, indicating a potential upside of 376.19%. Given CASI Pharmaceuticals' higher possible upside, equities analysts plainly believe CASI Pharmaceuticals is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Imunon has lower revenue, but higher earnings than CASI Pharmaceuticals. Imunon is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Imunon has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

Summary

CASI Pharmaceuticals beats Imunon on 8 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Creative Medical Technology?

CASI Pharmaceuticals (NASDAQ:CASI) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.90 beat CASI Pharmaceuticals' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Creative Medical Technology	Very Positive

Creative Medical Technology has lower revenue, but higher earnings than CASI Pharmaceuticals. Creative Medical Technology is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Creative Medical Technology	$10K	791.80	-$5.99M	-$2.14	N/A

Creative Medical Technology has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Creative Medical Technology	N/A	-88.38%	-84.71%

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market.

CASI Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

CASI Pharmaceuticals beats Creative Medical Technology on 9 of the 16 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Nuvilex?

Nuvilex (NASDAQ:PMCB) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Nuvilex has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Nuvilex and Nuvilex both had 1 articles in the media. Nuvilex's average media sentiment score of 0.87 beat CASI Pharmaceuticals' score of 0.00 indicating that Nuvilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvilex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvilex has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Nuvilex's return on equity of 2.13% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CASI Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvilex has higher earnings, but lower revenue than CASI Pharmaceuticals. Nuvilex is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Summary

Nuvilex and CASI Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.07	18.12	23.87	24.36
Price / Sales	0.10	303.59	521.52	117.07
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	1.73	3.95	9.99	6.73
Net Income	-$39.26M	$75.85M	$3.56B	$337.03M
7 Day Performance	N/A	-1.13%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-88.93%	23.03%	28.77%	33.98%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	0.9892 of 5 stars	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180	News Coverage
BFRI Biofrontera	0.7182 of 5 stars	$0.80 -1.5%	N/A	+48.2%	$10.18M	$41.71M	N/A	70	Analyst Upgrade
CURX Curanex Pharmaceuticals	1.4884 of 5 stars	$0.33 -0.9%	N/A	N/A	$9.32M	N/A	N/A	N/A	Positive News
IMNN Imunon	3.4669 of 5 stars	$2.20 flat	$10.00 +354.5%	-92.7%	$9.24M	N/A	N/A	30
CELZ Creative Medical Technology	1.2316 of 5 stars	$2.34 -2.1%	N/A	-4.6%	$8.66M	$10K	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. BFRI, CURX, IMNN, CELZ, and PMCB

How does CASI Pharmaceuticals compare to Biofrontera?

Summary

How does CASI Pharmaceuticals compare to Curanex Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to Imunon?

Summary

How does CASI Pharmaceuticals compare to Creative Medical Technology?

Summary

How does CASI Pharmaceuticals compare to Nuvilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. BFRI, CURX, IMNN, CELZ, and PMCB

How does CASI Pharmaceuticals compare to Biofrontera?

Is CASI or BFRI more profitable?

Do institutionals & insiders have more ownership in CASI or BFRI?

Does the media prefer CASI or BFRI?

Which has more volatility and risk, CASI or BFRI?

Do analysts prefer CASI or BFRI?

Which has preferable valuation & earnings, CASI or BFRI?

Summary

How does CASI Pharmaceuticals compare to Curanex Pharmaceuticals?

Do analysts prefer CURX or CASI?

Do insiders & institutionals believe in CURX or CASI?

Is CURX or CASI more profitable?

Does the media favor CURX or CASI?

Which has preferable valuation and earnings, CURX or CASI?

Summary

How does CASI Pharmaceuticals compare to Imunon?

Does the media refer more to CASI or IMNN?

Is CASI or IMNN more profitable?

Do analysts recommend CASI or IMNN?

Do institutionals & insiders believe in CASI or IMNN?

Which has higher valuation and earnings, CASI or IMNN?

Which has more volatility & risk, CASI or IMNN?

Summary

How does CASI Pharmaceuticals compare to Creative Medical Technology?

Does the media refer more to CASI or CELZ?

Which has better earnings & valuation, CASI or CELZ?

Is CASI or CELZ more profitable?

Do institutionals & insiders hold more shares of CASI or CELZ?

Which has more risk & volatility, CASI or CELZ?

Do analysts prefer CASI or CELZ?

Summary

How does CASI Pharmaceuticals compare to Nuvilex?

Which has more risk & volatility, PMCB or CASI?

Does the media favor PMCB or CASI?

Is PMCB or CASI more profitable?

Do institutionals and insiders have more ownership in PMCB or CASI?

Do analysts rate PMCB or CASI?

Which has stronger earnings and valuation, PMCB or CASI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools